GH-axis research
GHRP-2
Péptido de investigación de señalización endocrina liofilizado para revisión de sistemas
GHRP-2 is a growth hormone secretagogue research peptide studied around ghrelin-receptor activity and GH-release models.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Mantener sellado, frío, seco y protegido de los cambios de calor. Confirme el almacenamiento específico del producto a su llegada.
Empaquetado para estabilidad en tránsito con soporte de pedidos disponible para rutas en climas cálidos.
Batch-linked certificate support is available through the documentation desk.
Contexto de investigación
Perfil de investigación de GHRP-2
GHRP-2 is a synthetic growth hormone secretagogue studied through the ghrelin receptor pathway. Research examines GH-release magnitude and timing, endocrine-response markers, receptor pharmacology, appetite-related observations, and comparisons with GHRP-6, ipamorelin, or GHRH analogs. Its experimental profile is not identical to ipamorelin, which is often studied for greater selectivity, or GHRP-6, which is frequently associated with stronger appetite-pathway observations. GHRP-2 is useful as an established secretagogue comparator in GH-axis work. Study design should separate direct GHS-R signaling from GHRH-receptor activity and should not translate endocrine findings into personal-use or treatment recommendations.
Molecular class
Six-residue GH secretagogue
Sequence / composition
D-Ala-D-beta-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2; a short peptide with D-amino-acid substitutions.
Research design note
Its non-natural residues are part of the GHS-R pharmacology and should be distinguished from a native ghrelin sequence.
Mecanismo propuesto
A synthetic agonist at GHS-R1a. It stimulates pituitary growth-hormone release and also engages hypothalamic ghrelin-related pathways; endocrine selectivity is lower than that reported for ipamorelin.
Efectos reportados en estudios
- Human studies reported marked acute GH release, with responses influenced by dose, age, nutrition, and concurrent GHRH signaling.
- Studies also reported appetite-related effects and changes in ACTH, cortisol, or prolactin under some conditions.
- Repeated exposure can produce altered responsiveness or desensitization depending on the experimental schedule.
Criterios de investigación comunes
GHS-R potency, GH peak and area under the curve, ACTH, cortisol, prolactin, food intake, glucose, receptor desensitization, and synergy experiments with GHRH.
Evidencia y limitaciones
Human endocrine pharmacology and preclinical evidence exist, but long-term effects and catalog-product equivalence are not established.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.